BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, including additional analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS).

Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021.

Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference.

Octave, the developer of a fully-integrated Precision Care Solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), today announced the presentation of data based on eight posters at the ACTRIMS Forum 2022.

enVVeno Medical Corporation announced that positive thirty-month VenoValve first-in-human data was presented at the 34th Annual Meeting of the American Venous Forum being held February 23-26, 2022 in Orlando, Florida.

23andMe Holding Co. announced that management will be presenting at the Cowen 42nd Annual Health Care Conference on March 7, 2022 at 2:50 p.m. Eastern Time.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion for VBI’s 3-antigen hepatitis B (HBV) vaccine, under the brand name PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)].

Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced today that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement.

IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification technology.

Castellum, Inc. (OTC: ONOV) announces the signing of a “Definitive Purchase Agreement” to acquire Lexington Solutions Group (“LSG”), a $4 million government contractor focused on information operations - www.lexsg.com.